BMRA — Biomerica Income Statement
0.000.00%
Last trade - 00:00
- $12.28m
- $6.97m
- $5.34m
- 14
- 32
- 39
- 18
2019 May 31st | R2020 May 31st | 2021 May 31st | R2022 May 31st | 2023 May 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K/A | 10-K/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5.2 | 6.69 | 7.2 | 18.9 | 5.34 |
Cost of Revenue | |||||
Gross Profit | 1.29 | 1.74 | 0.366 | 2.98 | 0.446 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 7.61 | 9.43 | 14.7 | 23.4 | 12.6 |
Operating Profit | -2.41 | -2.74 | -7.5 | -4.53 | -7.22 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.37 | -2.67 | -7.43 | -4.51 | -7.09 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.39 | -2.68 | -7.45 | -4.53 | -7.14 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.39 | -2.68 | -7.45 | -4.53 | -7.14 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.39 | -2.68 | -7.45 | -4.53 | -7.14 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.26 | -0.263 | -0.624 | -0.358 | -0.504 |